Appia Bio
Jason Damiano is currently the Chief Scientific Officer at Appia Bio, where Jason focuses on creating allogeneic cell therapies for oncology and autoimmune disease. With a background in oncology biological therapeutics, Jason has experience in leading global drug discovery projects and developing novel technologies in the biotech industry. Prior to their current role, Jason held various leadership positions at companies such as UNITY Biotechnology, Achaogen, and Novartis, contributing to the discovery and development of therapeutic antibodies and small molecules for different disease indications. Jason's expertise also extends to immuno-oncology target identification and ADC discovery, showcasing their diverse skill set in the field.
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).